PMGC Holdings Inc. (NASDAQ:ELAB) ("PMGC" or the "Company") today announced that its wholly-owned subsidiary, NorthStrive Biosciences, Inc. ("NorthStrive"), has filed two new U.S. patent applications expanding the Company's EL-22 and EL-32 intellectual property portfolio into potential human pharmaceutical applications for the preservation of lean muscle mass during GLP-1 and obesity-related weight loss. The applications have been assigned U.S. Patent Application Nos. 19/709,895 (EL-22) and 19/709,950 (EL-32).

The new patent applications build on NorthStrive's previously announced intellectual property strategy for EL-22 and EL-32 and represent a strategic expansion from animal health and agricultural applications into potential human-use applications. The filings are directed toward preserving lean muscle mass in human patients experiencing muscle loss from sarcopenia, obesity-related weight loss treatment, malnutrition, neurogenic atrophy, or physical inactivity.

Disclaimer:This article represents the opinion of the author only. It does not represent the opinion of Webull, nor should it be viewed as an indication that Webull either agrees with or confirms the truthfulness or accuracy of the information. It should not be considered as investment advice from Webull or anyone else, nor should it be used as the basis of any investment decision.